Optiscan has been featured in an article in Stockhead, The Australian and 11 News Corp mastheads, examining the company’s commercialisation strategy, regulatory pathway and expanding clinical development programs in both veterinary and human healthcare markets.

The article highlights Optiscan’s submission of its InSpecta veterinary imaging platform to the US Food and Drug Administration’s Center for Veterinary Medicine, with the company targeting a commercial launch later this year. While InSpecta is expected to be Optiscan’s first commercialised product, the report notes that the company remains focused on advancing its human healthcare imaging platforms, including the InVue precision surgery device and Inform digital pathology device.

The article also references Optiscan’s ongoing breast cancer imaging study at The Royal Melbourne Hospital and head and neck cancer study at St John of God Murdoch Hospital, with data from these trials expected to support planned FDA submissions for Invue and Inform by the end of calendar 2026. In addition, the report highlights the company’s collaboration with Mayo Clinic, where future breast and head and neck cancer studies are planned.

CEO and Managing Director Dr Camile Farah said: “We have spent nearly 20 years validating and miniaturising the tech, to the degree the surgeon has a microscope in the palm of their hands. We can get into any nook and cranny in your body and we can do it live and in real time.”

Stockhead – Read the full article here.
The Australian – Read the full article here.